Alpha Tau Medical (DRTS) Gains from Sales and Divestitures (2022 - 2025)

Alpha Tau Medical has disclosed Gains from Sales and Divestitures across 4 years of filings, most recently posting $861192.0 for Q4 2025.

• Gains from Sales and Divestitures for Q4 2025 came in at $861192.0, up 25.29% year-over-year; the trailing twelve-month figure through Dec 2025 was $861192.0 (up 25.29% YoY), and the FY2025 annual result was $861192.0, up 25.29% from the prior year.
• Gains from Sales and Divestitures came in at $861192.0 for Q4 2025 at Alpha Tau Medical, up from $687356.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $861192.0 in Q4 2025 to a low of $232360.0 in Q4 2022.
• The 4-year median for Gains from Sales and Divestitures is $570593.5 (2023), against an average of $558684.8.
• Across the five-year window, Gains from Sales and Divestitures surged 95.31% in 2023 and rose 25.29% in 2025, its largest moves.
• Alpha Tau Medical's Gains from Sales and Divestitures stood at $232360.0 in 2022, then surged by 95.31% to $453831.0 in 2023, then soared by 51.46% to $687356.0 in 2024, then rose by 25.29% to $861192.0 in 2025.
• The last three Gains from Sales and Divestitures figures came in at $861192.0 (Q4 2025), $687356.0 (Q4 2024), and $453831.0 (Q4 2023), per Business Quant data.